Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genasys Inc.GNSS · Entity 7058 | Director | April 27, 2022 | April 27, 2022 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | June 14, 2023 | June 17, 2023 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Chief Financial Officer | May 10, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genasys Inc.
Report date April 27, 2022 · Filed April 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,311 |
Reported balance
After 2022-04-27 transaction · row 1
1 source rowRow 1 · 2022-04-27 · Exercise / conversion · Acquired 50,000 · Balance 284,311 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2022-05-10 | Direct | 0 |
Reported balance
After 2022-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-04-27 · Exercise / conversion · Disposed 50,000 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirectspouse | 2,000 |
Reported balance
Holding disclosure · report date 2022-04-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,000 |
STANDARD BIOTOOLS INC.
Report date June 14, 2023 · Filed June 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,791 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 26,376 · Balance 104,791 F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-06-14 | Direct | 35,380 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 35,380 · Balance 35,380 F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.
F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.
Travere Therapeutics, Inc.
Report date May 10, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,655 |
Ending reported balance
After 2022-05-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-10 · Sale · Disposed 825 · Balance 37,030 F1: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Row 2 · 2022-05-11 · Sale · Disposed 1,375 · Balance 35,655 F1: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2023 Filed Jun 17, 2023 00:41 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 35,380 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001162194-23-000041 · wk-form4_1686962510.xml · derivative · entry 2 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,380 Underlying: Common Stock · 35,380 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:41 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 26,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000041 · wk-form4_1686962510.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,791 F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 42,571 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001162194-22-000075 · wf-form4_165550345180060.xml · derivative · entry 2 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,571 Underlying: Common Stock · 42,571 shares Expires 2032-06-15 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:04 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 30,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000075 · wf-form4_165550345180060.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,415 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · balance_after: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,375 | $21.51 | $29,576.25 |
DisclosureSEC source: 0001209191-22-028707 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,655 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:45 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 825 | $21.51 | $17,745.75 |
DisclosureSEC source: 0001209191-22-028707 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,030 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 27, 2022 Filed Apr 27, 2022 23:02 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionStock Option · Derivative | 50,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001437749-22-009944 · rdgdoc.xml · derivative · entry 3 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2022 Filed Apr 27, 2022 23:02 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionCommon Stock | 50,000 | $1.33 | $66,500.00 |
DisclosureSEC source: 0001437749-22-009944 · rdgdoc.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 19:36 UTC | Genasys Inc. GNSS · Entity 7058 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-006570 · rdgdoc.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,311 F1 · price: On March 15, 2022, the issuer granted to the reporting person 30,000 restricted stock units (RSUs) that vest on the anniversary date of the grant. Each RSU represents a contingent right to one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 18:54 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001437749-22-004289 · rdgdoc.xml · derivative · entry 4 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 18:54 UTC | Genasys Inc. GNSS · Entity 7058 | SaleCommon Stock | 13,716 | $3.14 | $43,068.24 |
DisclosureSEC source: 0001437749-22-004289 · rdgdoc.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,311 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $3.10 to $3.20, inclusive. The reporting owner undertakes to provide Genasys Inc. and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 of this Form 4. F1 · acquired: The reporting person disposed of these shares to cover the cost and tax withholding obligations related to exercising the options that were scheduled to expire March 18, 2022. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 18:54 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionCommon Stock | 20,000 | $2.16 | $43,200.00 |
DisclosureSEC source: 0001437749-22-004289 · rdgdoc.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 5 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F6 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date. F6 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 9,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 4 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,840 Underlying: Common Stock · 9,840 shares Expires not disclosed F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date. F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 39,360 | $0.00 Strike: $27.50 | $0.00 |
DisclosureSEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 3 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,360 Underlying: Common Stock · 39,360 shares Expires 2032-01-30 F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,238 | $27.40 | $33,921.20 |
DisclosureSEC source: 0001209191-22-006362 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,855 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:17 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 9,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006362 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,093 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 21:34 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,063 | $24.98 | $51,533.74 |
DisclosureSEC source: 0001209191-22-005080 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,253 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,500 | $27.40 | $205,500.00 |
DisclosureSEC source: 0001209191-22-003046 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,316 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003046 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,816 F1 · kind: On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 23:34 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,407 | $17.12 | $24,085.31 |
DisclosureSEC source: 0001209191-21-052077 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,316 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 23:34 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052077 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,723 F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:28 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 15,402 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001162194-21-000059 · wf-form4_162215080437619.xml · derivative · entry 2 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,402 Underlying: Common Stock · 15,402 shares Expires 2031-05-25 F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on June 25, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:28 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 10,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000059 · wf-form4_162215080437619.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,501 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of May 25, 2022 and one day prior to the date of the Company's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · balance_after: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:07 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,000 | $19.46 | $38,920.00 |
DisclosureSEC source: 0001209191-21-032314 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,223 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:07 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,000 | $19.14 | $38,280.00 |
DisclosureSEC source: 0001209191-21-032314 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,223 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:52 UTC | Genasys Inc. GNSS · Entity 7058 | GrantCommon Stock | 27,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-006509 · rdgdoc.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,027 F1 · price: On March 16, 2021, the issuer granted to the reporting person 27,883 restricted stock units (RSUs) that vest on the one year anniversary of the date of grant. Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock. F1 · acquired: On March 16, 2021, the issuer granted to the reporting person 27,883 restricted stock units (RSUs) that vest on the one year anniversary of the date of grant. Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:43 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001437749-21-005857 · rdgdoc.xml · derivative · entry 3 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:43 UTC | Genasys Inc. GNSS · Entity 7058 | SaleCommon Stock | 5,456 | $7.42 | $40,464.97 |
DisclosureSEC source: 0001437749-21-005857 · rdgdoc.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,144 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.40 to $7.465, inclusive. The reporting owner undertakes to provide Genasys Inc. and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 of this Form 4. F1 · acquired: The reporting person disposed of these shares to cover the cost and tax withholding obligations related to exercising the options that were scheduled to expire March 26, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 17:43 UTC | Genasys Inc. GNSS · Entity 7058 | Exercise / conversionCommon Stock | 20,000 | $2.02 | $40,400.00 |
DisclosureSEC source: 0001437749-21-005857 · rdgdoc.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2021 Filed Feb 24, 2021 02:58 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 9,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000009 · wf-form4_161413548118979.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,159 F1 · shares: Represents Restricted Stock Units that vest in four equal quarterly installments beginning on March 15, 2021. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · balance_after: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 21:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,250 | $31.58 | $71,055.00 |
DisclosureSEC source: 0001209191-21-008802 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,223 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:29 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,250 | $31.41 | $70,672.50 |
DisclosureSEC source: 0001209191-21-008802 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,473 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,125 | $28.91 | $32,523.75 |
DisclosureSEC source: 0001209191-21-007632 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,223 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,500 | $28.91 | $72,275.00 |
DisclosureSEC source: 0001209191-21-007632 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,348 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 21:46 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008111 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,723 F1 · kind: (1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 02:19 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,125 | $30.75 | $34,593.75 |
DisclosureSEC source: 0001209191-21-007024 · doc4.xml · nonDerivative · entry 3 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,848 F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 02:19 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,500 | $30.75 | $76,875.00 |
DisclosureSEC source: 0001209191-21-007024 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,973 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| January 31, 2021 Filed Feb 3, 2021 02:19 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007024 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,473 F1 · kind: On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 01:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 57,500 | $0.00 Strike: $26.88 | $0.00 |
DisclosureSEC source: 0001209191-21-005250 · doc4.xml · derivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2031-01-20 F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 21, 2021 Filed Jan 26, 2021 01:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-005250 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,473 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years. Read SEC document |
| November 25, 2020 Filed Nov 26, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,750 | $22.72 | $85,200.00 |
DisclosureSEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 3 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| November 24, 2020 Filed Nov 26, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,750 | $23.86 | $89,475.00 |
DisclosureSEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,223 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| November 23, 2020 Filed Nov 26, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-060591 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,973 F1 · kind: On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 23, 2020, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 02:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 7,500 | $23.98 | $179,812.50 |
DisclosureSEC source: 0001209191-20-058945 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $24.485, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 13, 2020 Filed Nov 14, 2020 02:24 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 7,500 | $23.61 | $177,071.25 |
DisclosureSEC source: 0001209191-20-058417 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,973 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $24.105, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 02:24 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-058417 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,473 F1 · kind: On May 19, 2016, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition. Read SEC document |
| September 23, 2020 Filed Sep 24, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,500 | $18.48 | $27,720.00 |
DisclosureSEC source: 0001209191-20-051732 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 01:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,500 | $18.59 | $27,885.00 |
DisclosureSEC source: 0001209191-20-051612 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,973 F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:18 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051612 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,473 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.